NCT00062907View on ClinicalTrials.gov

Safety and Immunogenicity of Recombinant DNA and Adenovirus Expressing L523S Protein in Early Stage Non-Small Cell Lung Cancer

PHASE1UnknownINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

May 31, 2003

Conditions
Non-Small Cell Lung Cancer
Interventions
BIOLOGICAL

Recombinant DNA- pVAX/L523S

BIOLOGICAL

Recombinant adenovirus- Ad/L523S

Trial Locations (5)

34761

RECRUITING

Cancer Centers of Florida, Ocoee

75246

RECRUITING

Mary Crowley Medical Research Clinic, Dallas

75702

RECRUITING

Tyler Cancer Center, Tyler

98104

RECRUITING

Swedish Cancer Institute, Seattle

99218

RECRUITING

Cancer Care Northwest, Spokane

Sponsors

Lead Sponsor

Corixa Corporation
All Listed Sponsors
lead

Corixa Corporation

INDUSTRY

NCT00062907 - Safety and Immunogenicity of Recombinant DNA and Adenovirus Expressing L523S Protein in Early Stage Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter